Today: 30 April 2026
Browse Category

NASDAQ:ARTV 17 October 2025 - 16 December 2025

Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next

Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next

Artiva Biotherapeutics shares surged to around $6.30 on December 16 after trading between $4.08 and $7.25 in a session with volume near 48 million shares. CEO Fred Aslan disclosed selling 3,187 shares at $6.00 each on December 15 under a pre-arranged plan, according to an SEC Form 4. The company’s market cap stands near $155 million.
16 December 2025
Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

Artiva Biotherapeutics shares surged nearly 100% in after-hours trading Oct. 16 after the FDA granted Fast Track status to its AlloNK cell therapy for refractory rheumatoid arthritis. The stock jumped from a $2.77 close to as high as $6.33. Over 20 patients have received AlloNK in trials, with key safety and mechanistic data expected by mid-November. Artiva plans to begin a pivotal Phase 3 trial in 2026, pending results.
17 October 2025
·

Stock Market Today

  • Xerox Q1 CY2026 Earnings Beat Revenue Expectations, Shares Surge 12.7%
    April 30, 2026, 8:00 AM EDT. Xerox (NASDAQ:XRX) posted a strong Q1 CY2026 with revenue up 26.7% year-on-year to $1.85 billion, surpassing analysts' $1.73 billion estimates by 6.6%. Despite this, its full-year revenue guidance of $7.5 billion is 1% lower than projected. The company reported a smaller non-GAAP loss per share of $0.11, beating estimates by 60%, though adjusted EBITDA fell 47.4% short of forecasts. Operating margin slid to -4%, down from a slight positive last year, and free cash flow was negative $165 million. CEO Louie Pastor cited progress in revenue and profitability trends alongside enhanced liquidity. Xerox's modest long-term revenue growth at 1.5% annually suggests challenges in market expansion, but recent two-year growth of 5.4% hints at potential improvement.

Latest article

Microsoft Corporation’s $190 Billion AI Bet Is the Number Wall Street Can’t Ignore

Microsoft Corporation’s $190 Billion AI Bet Is the Number Wall Street Can’t Ignore

30 April 2026
Microsoft set a $190 billion budget for its 2026 AI expansion and forecast Azure growth above Wall Street expectations, but warned of sharply higher data-center costs. Fiscal third-quarter revenue rose 18% to $82.9 billion, with net income up 23% to $31.8 billion. Shares dipped 1.1% to $424.46 in premarket trading. Microsoft ended its exclusive deal to sell OpenAI models, opening the door for OpenAI to work with rivals.
Amazon Stock Rises on AWS AI Growth — Why AMZN’s Cloud Beat Matters Now

Amazon Stock Rises on AWS AI Growth — Why AMZN’s Cloud Beat Matters Now

30 April 2026
Amazon Web Services reported 28% revenue growth to $37.6 billion, its fastest in 15 quarters, pushing Amazon shares up 1.4% early Thursday. First-quarter net sales rose 17% to $181.5 billion, with net income at $30.3 billion, boosted by gains from Anthropic. Amazon forecast second-quarter sales of $194–$199 billion. Google Cloud grew 63% to $20 billion, outpacing AWS’s growth rate.
Why Intel Stock Hit a Record: Google AI Chip Report Puts Foundry Turnaround in Focus

Why Intel Stock Hit a Record: Google AI Chip Report Puts Foundry Turnaround in Focus

30 April 2026
Intel shares hit a record $94.75 early Thursday, up 12%, after reports that Google may use Intel’s EMIB packaging for next-generation AI chips. Intel Foundry posted $5.42 billion in Q1 revenue but lost $2.44 billion. Apple is also evaluating Intel’s 18A-P process for M-series chips, according to TrendForce. Google and Intel recently announced a multiyear partnership on AI and cloud infrastructure.
Go toTop